Vericel Co. (NASDAQ:VCEL) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 560,419 shares of the biotechnology company's stock after acquiring an additional 97,952 shares during the quarter. Federated Hermes Inc. owned 1.17% of Vericel worth $19,957,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of VCEL. William Blair Investment Management LLC lifted its stake in shares of Vericel by 59.5% during the 3rd quarter. William Blair Investment Management LLC now owns 855,207 shares of the biotechnology company's stock worth $28,667,000 after purchasing an additional 318,916 shares during the last quarter. Comerica Bank lifted its stake in shares of Vericel by 61,063.9% during the 3rd quarter. Comerica Bank now owns 208,569 shares of the biotechnology company's stock worth $6,991,000 after purchasing an additional 208,228 shares during the last quarter. FMR LLC lifted its stake in shares of Vericel by 39.5% during the 3rd quarter. FMR LLC now owns 571,298 shares of the biotechnology company's stock worth $19,150,000 after purchasing an additional 161,652 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Vericel by 35.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 540,209 shares of the biotechnology company's stock worth $18,108,000 after purchasing an additional 141,488 shares during the last quarter. Finally, Congress Asset Management Co. MA purchased a new stake in shares of Vericel during the 3rd quarter worth $4,048,000.

Vericel Trading Up 3.7 %

Shares of VCEL stock traded up $1.64 during mid-day trading on Monday, reaching $45.38. The stock had a trading volume of 300,916 shares, compared to its average volume of 551,660. The business's fifty day moving average is $47.58 and its 200-day moving average is $40.46. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -485.95 and a beta of 1.71. Vericel Co. has a 1-year low of $29.24 and a 1-year high of $53.05.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.08. The business had revenue of $65.00 million for the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company's revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.12 earnings per share. On average, analysts forecast that Vericel Co. will post 0.09 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total transaction of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares in the company, valued at $8,708,739.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total transaction of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares in the company, valued at $8,708,739.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,300 shares of Vericel stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $44.22, for a total value of $101,706.00. Following the transaction, the director now owns 23,395 shares of the company's stock, valued at $1,034,526.90. The disclosure for this sale can be found here. Insiders have sold a total of 56,767 shares of company stock valued at $2,561,506 over the last ninety days. Company insiders own 7.20% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on VCEL. HC Wainwright upped their price objective on Vericel from $46.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Truist Financial reaffirmed a "buy" rating and set a $54.00 target price on shares of Vericel in a research report on Tuesday, March 26th. Finally, TheStreet raised Vericel from a "d+" rating to a "c-" rating in a research report on Monday, January 29th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $46.40.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.